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Abstract
Discordant results obtained in bisulfite assays using MethPrimers (PCR primers designed
using MethPrimer software or assuming that non-CpGs cytosines are non methylated) ver-
sus primers insensitive to cytosine methylation lead us to hypothesize a technical bias. We
therefore used the two kinds of primers to study different experimental models and methyla-
tion statuses. We demonstrated that MethPrimers negatively select hypermethylated DNA
sequences in the PCR step of the bisulfite assay, resulting in CpGmethylation underestima-
tion and non-CpG methylation masking, failing to evidence differential methylation statuses.
We also describe the characteristics of “Methylation-Insensitive Primers” (MIPs), having de-
generated bases (G/A) to cope with the uncertain C/U conversion. As CpG and non-CpG
DNAmethylation patterns are largely variable depending on the species, developmental
stage, tissue and cell type, a variable extent of the bias is expected. The more the methy-
lome is methylated, the greater is the extent of the bias, with a prevalent effect of non-CpG
methylation. These findings suggest a revision of several DNA methylation patterns so far
documented and also point out the necessity of applying unbiased analyses to the increas-
ing number of epigenomic studies.
Introduction
It is generally accepted that DNA methylation almost exclusively occurs in CpG dinucleotides
in mammals [1–4]. Non-CpG methylation has been documented, but with limited extent (see
Discussion) and in specific cell types—mainly stem cells. Using the bisulfite modification fol-
lowed by PCR amplification, cloning and sequencing, we previously reported unexpectedly
high non-CpG methylation inmyogeninmouse promoter [5]. Moreover, in human PSEN1
promoter, we observed discordant methylation patterns when using PCR primers designed
using the MethPrimer software [6] (assuming that non-CpG cytosines are modified by
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bisulfite; defined as “MethPrimers” from now on) or primers designed to be insensitive to cyto-
sine-methylation status. When the bisulfite technique has been originally described [7, 8], it
was recommended not to include cytosines in the recognition sequence of the primers to avoid
possible mismatches depending on methylation status. Interestingly, the same authors were
able to evidence some non-CpG methylation in the first applications of the technique [9].
However, in the following years, MethPrimers became the most (if not exclusively) used prim-
ers in bisulfite-based applications, due to the advantage of the software-assisted primer design
and to the general assumption that non-CpG cytosines were mainly unmethylated. Although
the lack of a specific name makes it difficult to retrieve in PubMed the number of papers in
which they are used, looking at the citations of the original article describing the MethPrimer
software [6], it is possible to infer at least one thousand citations. Furthermore, an on line
search through Google Scholar evidences about 29300 articles in which the bisulfite approach
is used; among these, about 80% reports the use of MethPrimer software or similar primer
design strategy.
Despite this trend, we have always been using primers designed in regions without cytosines
or, when this was not possible, primers with degenerated bases (G/A) to cope with the uncer-
tain C/U conversion of the few (max. 3) cytosines residues included in the sequence of the
primer [5,10]. These primers will be here defined as “methylation-insensitive primers” (MIPs).
The high non-CpG methylation observed formyogenin and the discordant methylation profile
observed when PSEN1 was analyzed using either MethPrimers or MIPs lead us to hypothesize
that MethPrimers could negatively select non-CpG methylated DNA molecules also resulting
in a biased outcome of the CpG methylation assessment.
In order to verify this hypothesis, we analyzed two genes (myogenin and PSEN1), each one
in two experimental models: CD1 mouse embryos and C2C12 myoblast cells formyogenin and
human brains and neuroblastoma SK-N-BE cells for PSEN1. In each model, we compared con-
ditions with differential methylation profiles, as ascertained in previous studies [5, 10].
Results and Discussion
Samples were bisulfite-modified and then amplified by two primer sets, MethPrimers or MIPs,
recognizing the same promoter region (S1 Fig.); each sample was divided in two aliquots after
bisulfite conversion for amplification with the two primer sets and then processed in parallel
until the final sequencing step. Several positive and negative controls were performed to avoid
any possible technical bias (see Methods section).
Fig. 1 shows the methylation pattern of the 9 CpG sites investigated inmyogenin promoter
in C2C12 cells (Fig. 1A and 1B) and in mice tissues (Fig. 1C and 1D). Whenmyogeninmethyla-
tion is high as in cells grown in 10% FCS and in mouse embryonic brain, MethPrimers signifi-
cantly underestimate DNAmethylation levels. As a matter of fact, whereas Mann-Witney test
(used to evidence differences between two samples analyzed with the same primers) results in a
significant difference for all the cytosine moieties when comparing the hypermethylated
(Fig. 1A and 1C) vs. hypomethylated (Fig. 1B and 1D) experimental condition using MIPs
[Cells: U = 9.00, p<0.05; Tissues: U = 16.00, p<0.02], the same comparison using MethPrimers
indicates non-significant differences for 4 cytosines (1145, 1266, 1339, 1342). Moreover, Wil-
coxon test (used to evidence differences when comparing MIPs vs. MethPrimers assay in the
same sample) indicates that 5 cytosines result significantly hypomethylated when analyzed
with MethPrimers [cytosines 1145, 1266, 1350, 1355, 1368: Z = -1.6, p<0.05] in C2C12 myo-
blasts. This difference was much more evident in brain and muscle tissues: all the cytosines
(except the 1149) resulted significantly hypomethylated when the methylation assay is per-
formed using MethPrimers vs. MIPs in the most methylated condition [Z = -2.5, p<0.02]. It is
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Fig 1. MIPs and MethPrimers result in different CpGmethylation patterns.CpGmethylation pattern is expressed as percent methylation for each CpG in
the investigated region of the mousemyogenin (a-d) and human PSEN1 (e-h) promoters. Light grey columns show the values obtained using MIPs, dark grey
columns show the values obtained using MethPrimers. Time points for cell cultures are: 48 h for C2C12 10% FCS, SK-N-BE+SAM, SK-N-BE B def.; 24 h for
C2C12 1%FCS. Symbols: * p<0.05 MIPs vs. MethPrimers; &: p<0.05 High Methylated vs. Low Methylated with MIPs; §: p<0.05 High Methylated vs. Low
Methylated with MethPrimers. Y axes in histograms have a different scale (up to 100% for high methylated samples, up to 50% for low methylated samples)
in order to better evidence intra-sequence differences in cytosine methylation analyzed with Methprimers vs. MIPs.
doi:10.1371/journal.pone.0118318.g001
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therefore evident that in experimental conditions in which DNAmethylation is high MethPri-
mers show low power of detection compared to MIPs, eventually failing to evidence differences
between differential methylation in two samples.
Very similar results were obtained when studying DNAmethylation pattern of PSEN1 in
SK-N-BE cells grown in hypermethylating (S-adenosylmethionine supplemented) or hypo-
methylating (B vitamin deficiency) conditions [11] (Fig. 1E and F) and in frontal cortex sam-
ples from control subjects and patients with Alzheimer’s disease (AD) and control subjects
(Fig. 1G and H). Mann-Withney test resulted in 10 out of 24 cytosines moieties significantly
hypomethylated in PSEN1 promoter of low methylated (Fig. 1F) vs. high methylated (Fig. 1E)
SK-N-BE cells when MIPs were used [cytosines 974, 1019, 1035, 1141, 1154, 1172, 1191, 1217,
1224, 1226: U = 9.00, p<0.05]. On the contrary, only 1 cytosine resulted significantly hypo-
methylated in the same samples when MethPrimers were used [cytosines 1075: U = 9.00;
p<0.05]. This result was, also for PSEN1, more evident in tissues: all the cytosines analyzed
were significantly hypomethylated in AD brains vs. controls [U = 16.00, p<0.05] whereas only
5 cytosines resulted hypomethylated when studied using MethPrimers [cytosines 1028, 1145,
1154, 1191, 1226: U = 16.00, p<0.05]. The inter-assay variation was confirmed by Wilcoxon
test also for PSEN1; as a matter of fact, all the cytosines resulted significantly hypomethylated
when the assay was performed using MethPrimers vs. MIPs [SK-N-BE cells: Z = -2.52, p<0.05;
brain: Z = -2.52, p<0.02]. Therefore, assessing methylation with MethPrimers can result in un-
derestimation of the high methylation levels eventually biasing the detection of differences.
The Sanger sequencing after bisulfite modification allows detecting the methylation level of
any individual cytosine in the whole amplified region, including non-CpG cytosines [7, 8]. As
previously observed formyogenin promoter [5] (S2 Fig.), when sequencing PCR products am-
plified using MIPs we were able at evidencing discrete non-CpG methylation also in PSEN1
promoter (S3 Fig.) at least in the conditions of high methylation [myogenin: Z = -2.91, p<0.01;
PSEN1: Z = -3.13, p<0.01]. It is worth of note that, whereas MIPs allow discriminating between
conditions with high/discrete and low/absent non-CpG methylation, MethPrimers invariably
fail to evidence it (S2 and S3 Figs.). This observation raises two considerations: i) from the tech-
nical point of view it is evident that the described underestimation of DNA methylation when
MethPrimers are used is due to the inability of these primers to bind non-CpG-methylated se-
quences; ii) from a perspective point of view, it can be inferred that the use of these primers has
been causing general underestimation of the non-CpG methylation.
In order to confirm these observations by an independent approach, we also compared, by
real-time PCR on bisulphite-modified genomic DNA, the amplification efficiency of each
primer set respect to differential methylation statuses (Fig. 2). Fig. 2A and 2B show the overall
non-CpG methylation levels measured, respectively, formyogenin and PSEN1 promoter, in dif-
ferent experimental conditions, ordered according to increasing methylation. Fig. 2C and 2D
demonstrate that whereasmyogenin and PSEN1MIPs correctly amplify with similar efficiency
all bisulfite-modified DNA samples independently on their original non-CpG methylation sta-
tus (light gray columns), MethPrimers show significant inverse correlation [myogenin: r = 0.94,
p<0.001; PSEN1: r = 0.89, p<0.001] between amplification efficiency and DNAmethylation
level. This result indicates that the more DNA is non-CpG methylated, the less MethPrimers
are able to bind to the bisulfite-modified product indicating that these primers negatively select
the high methylation (poorly modified) DNA fraction in the sample. As expected, MethPri-
mers failed to amplify untreated PCR products whereas MIPs show similar amplification effi-
ciency for both treated and untreated PCR fragments.
Finally, we used a third independent experimental approach to demonstrate that non-CpG
methylation was present in the samples we analyzed. To this end, DNA samples with differen-
tial methylation levels were digested by non-CpG methylation-sensitive and methylation-
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insensitive endonucleases. Endonuclease assays formyogenin were already published [5],
whereas the assay on PSEN1 is shown in S4 Fig. The results also indicate that the cutting effi-
ciency is impaired in DNA samples with high methylation.
These experiments show that MethPrimers, commonly used in the PCR step of several bi-
sulfite-based assays for the study of DNA methylation, can give false negative results (no meth-
ylation differences) due to their selective binding to the DNA fraction with lower methylation.
Fig 2. MethPrimers amplification efficiency is affected by DNAmethylation. a)Myogenin and b) PSEN1 overall non-CpGmethylation. c) and d)
Amplification efficiency of primers on samples with differential overall non-CpGmethylation was assessed by Real-Time PCR assay using MIPs (light grey
columns) or MethPrimers (dark grey columns) formyogenin (c) and PSEN1 (d). Bisulphite-treated PCR products and untreated PCR products were used as
control of amplification efficiency. Values are expressed as fold n° versus control (C2C12 in 1% 24 hours formyogenin, SK-N-BE in complete medium for
PSEN1 used as respective calibrators);myogenin amplification values were normalized using PSEN1 PCR product amplification (added to mouse samples
and used as exogenous reference) whereas PSEN1 amplification values were normalized tomyogenin PCR product amplification (in this case added to
human samples and used as exogenous reference). *: p<0.001 vs. ctrl.
doi:10.1371/journal.pone.0118318.g002
MethPrimers Underestimate DNAMethylation
PLOS ONE | DOI:10.1371/journal.pone.0118318 February 18, 2015 5 / 12
This problem particularly affects highly methylated samples whereas samples with low methyl-
ation are unaffected; the use of MIPs allows bypassing this deficiency. We do not affirm that all
the data so far obtained using MethPrimers are biased, but suggest being more cautious when
“no differences” in methylation patterns are found. It is likely that a number of (mainly nega-
tive) findings obtained with MethPrimers could benefit from a verification using MIPs. These
data were obtained for two independent genes, in two different organisms, each one in two ex-
perimental models; this approach appears sufficient to sustain the disclosure of the technical
bias. A genome-wide confrontation between MIPs and MethPrimers appears beyond the scope
of this technical report and could be probably not resolutive, since we demonstrated that the
bias is evident only in conditions of high DNA methylation. However, the comparison of the
epigenome as evaluated by the two kinds of primers would be a natural prosecution of the ex-
periments here reported.
Finally, although the aim of this paper is not to evidence discrete non-CpG methylation in
differentiated cells, we cannot ignore that our data strongly point out the idea that non-CpG
methylation extent and role are probably underestimated. Indeed, recent evidences using unbi-
ased techniques like Whole Genome Bisulphite Sequencing (WGBS) stress a functional role for
non-CpG methylation [12–15]. Noteworthy, non-CpG methylation was demonstrated not just
at genomic but at specific gene level [16–18] and particularly in brain [19, 20]. We therefore
suggest that unbiased approaches, not based on the use of MethPrimers, are used to further in-
vestigate the role of non-CpG methylation in gene-specific and genome-wide analyses. As CpG
and non-CpG DNAmethylation patterns are largely variable depending on the species, devel-
opmental stage, tissue and cell type, a variable extent of the bias is expected. The more the
methylome is methylated, the greater is the extent of the bias, with a prevalent effect of non-
CpG methylation.
DNA methylation patterns and quantitative levels of methylation are largely variable in
different tissues and cell types, as well as during development and differentiation. Several ex-
perimental evidences have been published on the fact that, despite similar levels of CpG meth-
ylation, mouse embryonic stem cells (ESCs) have considerably higher levels of non-CpG
methylation (from 15 to 20% of total cytosine methylation), depending to the ability of
DNMT3a, DNMT3b and DNMT3L to catalyze and regulate it [1, 14]. Even though these “first
generation” studies were based on the analysis of a small fraction of the genome, they have
been fully confirmed by subsequent “next generation” studies.
Genome-wide single-base-resolution maps of cytosine methylation in humans demonstrat-
ed that in ESCs, as well as in induced pluripotent stem cells (IPSCs), the 12–25% of the cytosine
methylation is present in non-CpG context, is functionally linked to expression and is more
prevalent in gene bodies than in protein binding sites and enhancers [15, 21, 22].
Several papers have demonstrated that from the 25% to the 35% of total DNA methylation
in adult mouse and human brain resides in non-CpG sites, as measured by base-resolution
analyses of respective methylomes [19, 23–26]. These researches also demonstrated that this
kind of methylation is usually established de novo during neuronal maturation, conserved and
correlated with gene expression. It has also been demonstrated that a highly conserved non-
CpG methylation accumulates in human neurons during fetal to young adult development, to
even become, at some developmental stages, the dominant form of methylation (53%) of the
human neuronal genome [25].
Subsequent studies compared DNA methylation across diverse human cell line and tissue.
It is worth of note that, after ESCs and brain, the tissue with the highest level of non-CpG
methylation appeared to be the skeletal muscle [27]. However, quantitative data about the ratio
between CpG and non-CpG residues in skeletal muscle methylome are poor and affected by
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the bias introduced from the study of a reduced number of non-CpG and/or by the use of re-
striction digestion-based approaches, such as RRBS [15] or LUMA [12].
From methodological point of view, bisulfite treatment is, at moment, an unavoidable step
for studying DNAmethylation at single-C level. If the subsequent experimental steps are based
on strand-specific PCR performed by methylation-specific primers, the approach is potentially
biased by non-CpG methylation. It depends on the primer design. Among recent approaches
and analytical platforms used for genome wide methylation analysis (for a review see [28]),
those based on methods of enrichment for methylated DNA able to recognize also non-CpG
methylation and using bisulfite-insensitive adaptors, are expected to be unbiased. The compar-
ison between data obtained by previous single-gene methods potentially biased and those ob-
tained by the new unbiased approaches at methylome level, is likely to deserve amazing
differences about the extent, dynamics and role of non-CpG methylation.
Materials and Methods
Media and cell cultures
Cell cultures were performed as previously described [5, 10]. Briefly: murine myoblasts C2C12
and human neuroblastoma SK-N-BE cell were maintained in F14 medium with 10% FCS
(Growth Medium, GM). SK-N-BE cell line was a kind gift by A. Confaloni and G. Poiana and
was originally purchased from ATCC (American Type culture Collection, Rockville, MD,
USA). According to the experimental plan, cells were plated in GM and, after 24 h of growth,
were stopped or shifted to Differentiation Medium (DM) (time 0); the subsequent collection
times in GM and DM are indicated in figure legends. SK-N-BE cells were also treated with dif-
ferentiation medium deficient of folate, vitamin B12 and vitamin B6 (B deficient) or supple-
mented with S-adenosylmethionine (SAM 100 μM) according to the experimental design.
Experiments were repeated at least three times.
Animals
CD1 mice were housed in an air-conditioned room (temperature 21±1°C, relative humidity
60±10%) with 12:12 h light:dark cycle (lights on from 8 AM to 8 PM) and food and water
continuously available. Embryonic Brain and Muscle tissues were isolated from CD1 mouse
embryos (Ed7); 4 pools of 2 brains or muscles were used for each experimental condition as
previously described [10, 11].
All the experiments were performed in such a way as to sacrifice the minimum number of
animals required and were approved by author’s Institution (Sapienza University of Rome) in
accordance with the European Communities Council Directive (86/609/EEC) and formally ap-
proved by the Italian Ministry of Health (D.L. 92/116).
Human brain samples
Frozen post-mortem samples of the prefrontal cortex (area 8) from age-matched control
(n = 4) and Alzheimer’s disease patients (n = 4) staged VIC according to Braak and Braak’s no-
menclature were obtained with a postmortem delay between 4 and 6 hours, and immediately
frozen and stored at -80°C for molecular studies. The neuropathological study was carried out
following the recommendations derived from the European Brain Bank Network of Excellence
(http://www.brainnet-europe.org/) funded by the European Commission in the 6th Frame-
work Program "Life Science" (LSHM-CT-2004-503039) informed consent from the donors or
the next of kin were obtained for use of these samples in research. Specifically, historical sam-
ples in biobanks in which authorization cannot be retrieved can be used for research purposes
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following the approval of the local ethics committee according to the “Ley de la Ciencia" (Bole-
tin Oficial del Estado: BOE-A-2011-9617) and the “Real Decreto de Biobancos” (BOE-A-2011-
18919) for samples before the publication of the Real Decreto. All the samples obtained from
this date onwards are obtained following written consent, which is kept at the archives of the
HUB-ICO-IDIBELL biobank following the guidelines of the local Ethics Committee.
DNAmethylation studies by bisulphite modification and genomic
sequencing
DNA was extracted from cells and tissues by classical phenol-chloroform method [5]. Bisul-
phite analysis ofmyogenin and PSEN1 promoter methylation was performed using the EpiTect
Bisulphite kit; PCR products obtained after bisulphite treatment were cloned using the PCR
Plus Cloning Kit (both from Qiagen). At least ten clones were analyzed per experimental con-
dition using M13 primers for sequencing. Sequencing reactions of purified plasmid DNA were
performed. Clones were sequenced by the cycle sequencing method using the ABI PRISM
3130xl genetic analyzer (Applied Biosystems). Modified cytosine residues were recognized
through comparison with the original DNA sequence and methylation status of any single cy-
tosine in each sequenced clone were reported as 1/0 value in an excel spreadsheet (methylated:
1; unmethylated: 0). For each experimental sample we obtained the methylation % of each sin-
gle cytosine by calculating the number of methylated cytosines divided by the number of clone
sequenced per 100 ([n° methylC / n° sequenced clones] x100). Then, we calculated the average
methylation % over the replicated cell culture experiments or over the 4 tissue samples for each
experimental condition. Raw data related to DNA methylation results are shown in S5 Fig.
GenBank accession numbers, primer names, sequence and position, expected products and
annealing temperatures of the Methylation Insensitive Primers (MIPs) used for bisulphite anal-
ysis were already published [5, 10]. Sequence, characteristics and position of both MIPs and
MethPrimers are in S1 Fig. These primers allowed assessing methylation status of plus (5’->3’)
DNA strand.
We also used different bisulphite modification assays as random control in samples charac-
terized by low and high (CpG and non-CpG) methylation to ensure that cytosine conversion
was complete. In particular, standard bisulphite procedures [8] with modifications previously
described [10, 29] and a modified method with ammonium bisulphite [30] were used. In all
these cases the methylation patterns we found were similar. As negative controls of bisulphite
modifications we used unmethylated purified PCR products ofmyogenin and PSEN1 promoter,
obtained from genomic DNA as template with the sameMIPs primers used for bisulphite PCR;
the same purified PCR products where methylated in vitro with SssI methylase (New England
Biochemistry), that methylates only cytosines in CpG dinucleotides, and were used as positive
controls. We adopted all the possible cautions and controls to be sure that no methodological
troubles could bias our analysis. In particular: 1) DNA samples to be compared were purified in
parallel and modified in the same bisulfite assay; 2) amplifications with MIPs and with MethPri-
mers were performed on two aliquots of the same bisulfite-modified sample; 3) PCR products
obtained by both MIPs and MethPrimers were always cloned in the same assay; 4) positive and
negative controls were always used in each bisulfite assay; 5) clones were sequenced using two
different instruments (the in-lab Applied Biosystems instrument and in service by Primm).
Measurement of primers efficiency by PCR assay
SybrGreen PCR real-time assay was performed to assess the efficiency of amplification of MIPs
and MethPrimers in samples with differential DNAmethylation levels. 1 μg of DNA was used
in each real-time reaction, performed in triplicate as previously described [11]. Data are
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presented as fold increase (ratio of the experimental gene value / exogenous reference gene
value) over a control sample (the less methylated sample, used as calibrator). Since the assay re-
sults in a relative measure of the efficiency, we amplified in parallel exogenous mousemyogenin
as reference gene when assessing human PSEN1 amplification efficiency and exogenous
human PSEN1 when assessing mousemyogenin amplification efficiency. To this end, standard
amount (50 ng) of mousemyogenin or human PSEN1 PCR product were respectively added to
each sample before splitting it in the tubes for the amplification. We preliminary verified that
primers used to amplify mousemyogenin were not able to amplifymyogenin in human samples
and that those used to amplify human PSEN1 were not able to amplify PSEN1 in mouse sam-
ples. Additionally, bisulphite-treated and bisulphite-untreated PCR products were amplified as
controls; as expected, MethPrimers failed to amplify untreated PCR products.
DNA digestion and PCR assays
DNA digestion and PCR reactions were performed as previously described [31]. Briefly, 2 μg of
genomic DNA purified from SK-N-BE cells grown in condition of high and low methylation
(HM and LM, respectively) were treated at 37°C overnight with 6U and for further 6 hours
with other 4U of the PvuII, EcoNI and EcoRI restriction endonucleases. They have the follow-
ing characteristics in the amplified region of PSEN1 promoter: i) PvuII has one recognition site
at the cytosine 862 of the sequence and is sensitive to CpT methylation; ii) EcoNI has one rec-
ognition site at the position 1204 and is methylation insensitive; iii) EcoRI has no recognition
sites. The digested samples were then amplified as previously described by the same couple of
MIPs primers used for bisulphite analysis. All the electrophoresis gels were analyzed using a
computerized densitometer (Fluor-S, Bio-Rad). Controls with heat-inactivated endonucleases
and on non-methylated PCR products were performed. Specificity of digested samples was
confirmed by molecular weight comparison with DNAmolecular weight markers and
by sequencing.
Statistical analysis
Statview statistical software was used to calculate any significant difference reported in this
paper. Histograms show the mean value ± s.d. Asterisks in figures evidence the statistically sig-
nificant differences; differences lacking of remarks are to be considered non-significant.
Analysis on methylation data was performed using non-parametric tests since the experi-
mental method we applied (sequencing of at least 10 clones for each experimental replicate) re-
sults in percent values (methylation %) for many cytosines (non-correlated values) in each
sample. Mann-Wittney test was used to calculate inter-sample differences (i.e. when comparing
HM and LM samples); Wilcoxon test was used to calculate intra-sample differences (i.e. when
comparing MIPs and MethPrimers data).
One-way ANOVA was computed and Bonferroni post-test was used to evaluate any signifi-
cant difference in the Real-Time PCR assays. To assess the correlation between quantitative
variables, we computed the linear correlation coefficient r (Pearson’s) with the corresponding
significance level.
Ethical issues
Work on human subjects: post-mortem brains used in the present study were obtained from
the Institute of Neuropathology and Brain Bank (HUB-ICO-IDIBELL Biobank) following the
guidelines of the Declaration of Helsinki, and according to the Spanish and Catalonian Auton-
omous regulations on this matter, and the approval of the local Ethics Committee of the Bell-
vitge University Hospital. Work on vertebrate animals: embryonic mouse tissues used in the
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present study were collected in the Dept. of Surgery “P. Valdoni”, Sapienza University of Rome
after Institutional and National approval according to the EU laws.
Supporting Information
S1 Fig.Myogenin and PSEN1 promoters and PCR primers. a) Schematic representation of
the investigated region in mousemyogenin (up) and human PSEN1 (down) 5’-flanking regions.
Numbers on the left of the DNA sequences indicates the base-number as prorated in the Gene-
Bank sequences. MethylC-Insensitive Primers (MIPs) are indicated in bold-blue and MethPri-
mers are indicated in bold/underline. b) Characteristics of the oligonucleotides used as primers
to investigate mousemyogenin and human PSEN1methylation. The position of each primer is
indicated below the sequence.
(PDF)
S2 Fig. Complete Cytosine methylation profile ofmyogenin promoter. Histograms show the
methylation percent measured for each (both CpG and non-CpG) cytosine in the investigated
region of the mousemyogenin promoter. Light grey columns represent the result obtained by
using MIPs, whereas dark grey columns represent the results obtained by using MethPrimers.
a) C2C12 in 10% FCS (high methylation); b) C2C12 in 1% FCS (low methylation); c) Embry-
onic brain (high methylation); d) Embryonic muscle (low methylation). Detection of non-CpG
methylation is clearly defective when MethPrimers are used, particularly in high
methylation conditions.
(PDF)
S3 Fig. Complete Cytosine methylation profile of PSEN1 promoter. Histograms show the
methylation percent measured for each (both CpG and non-CpG) cytosine in the investigated
region of the human PSEN1 promoter. Light grey columns represent the result obtained by
using MIPs, whereas dark grey columns represent the results obtained by using MethPrimers.
a) SK-N-BE + SAM (high methylation); b) SK-N-BE in B vitamin deficient medium (low meth-
ylation); c) Cortical brain tissue from control subjects (high methylation); d) Cortical brain tis-
sue from Alzheimer’s Disease subjects (low methylation). As formyogenin, it is evident, also in
PSEN1 promoter, that detection of non-CpG methylation is defective when MethPrimers are
used, particularly in high methylation conditions.
(PDF)
S4 Fig. Restriction analysis of PSEN1 promoter. Non-CpG methylation was confirmed in
SK-N-BE cells by methylation-sensitive endonuclease assay on PSEN1 promoter in high meth-
ylated (HM) and low methylated (LM) samples. PvuII is inhibited when the target sequence is
methylated on the CpT moiety, as schematized in the table. PCR after incubation with the en-
zyme shows that HM sample and (at lower level) LM sample are incompletely cut, indicating
the presence of non-CpG methylation. Use of methylation-insensitive endonuclease (EcoNI)
and of unmethylated controls (PCR products) demonstrate that the DNA is not resistant for
other intrinsic factors and that PvuII is able at cutting when the target sequence is unmethy-
lated. MM: Molecular weight marker; PvuII Inact.: heat inactivated PvuII.
(PDF)
S5 Fig. Raw methylation data. Representation of the raw methylation data for each gene/ex-
perimental condition/sample/sequenced clone. Black boxes represent methylated cytosines,
white boxes represent unmethylated cytosines, as described in the graphic legend.
(PDF)
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Supplementary Figure 5  graphic legend
Light green: High methylated conditions / analyzed by MIPs
Dark green: Low methylated conditions / analyzed by MIPs
Light yellow: High methylated conditions / analyzed by MethPrimers
Dark yellow: Low methylated conditions / analyzed by MethPrimers
Black box: methylated cytosine
White box: unmethylated cytosine
Grey box: undetermined  
"Clone": Positive bacterial colonies sequenced per sample
"% methylation": % methylation for each cytosine in each sample
"Cytosine": position (bp) of cytosines in the promoter sequence (CpGs in red)




